arrow
S

Seung-Hwan Lee

seoul national university
H指数:56
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinically approved ALDH inhibitor combined with a chemotherapeutic agent sensitizes triple-negative breast cancer stem cells to PD-L1 blockade

临床批准的ALDH抑制剂与化疗药物联合应用可增强三阴性乳腺癌干细胞对PD-L1阻断的敏感性

2026-09-030
OA
Efficacy and Safety of Pregabalin and Alpha-Lipoic Acid Combination in Patients With Painful Diabetic Peripheral Neuropathy: A Randomized, Open-Label, Non-Inferiority, Phase IV Clinical Trial and Subgroup Analysis (OPTIMUM Study)

奥普瑞巴林和α-硫辛酸联合治疗痛性糖尿病周围神经病变的疗效与安全性:一项随机、开放标签、非劣效性、IV期临床研究及亚组分析(OPTIMUM研究)

2026-04-290
OAAI
Efficacy and safety of combining empagliflozin in people with type 2 diabetes mellitus uncontrolled with metformin and sitagliptin: A randomised, double-blind, multicentre, therapeutic confirmatory phase 3 clinical trial
2025-12-010
OAAI
Adenosine A2A receptor agonist polydeoxyribonucleotide ameliorates acetic acid-induced ulcerative colitis via modulating PI3K/Akt/VEGF signaling pathway

腺苷A2A受体激动剂聚脱氧核糖核苷酸通过调节PI3K/Akt/VEGF信号通路改善乙酸诱导的溃疡性结肠炎。

2025-08-200
PRE
Association between behavioral and sociodemographic factors and high subjective health among adolescents: a nationwide representative study in South Korea

行为和社会人口统计学因素与青少年高主观健康之间的关联: 韩国的一项全国性代表性研究

2025-01-070
OAAI
Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial
2024-07-311
OAAI